搜索临床试验以:INCB028050
总计14个结果
-
Eli Lilly and CompanyIncyte Corporation完全的
-
Massachusetts General Hospital招聘中
-
University of California, San Francisco终止ALK融合蛋白表达 | III 期皮肤黑色素瘤 | IIIA 期皮肤黑色素瘤 | IIIB 期皮肤黑色素瘤 | IIIC 期皮肤黑色素瘤 | IV 期皮肤黑色素瘤 | ROS1融合阳性 | BRAF 等位基因 | 侵袭性皮肤黑色素瘤 | MET融合基因阳性 | NRAS wt 等位基因 | NTRK1融合阳性 | NTRK2融合阳性 | NTRK3融合阳性 | RET融合阳性美国
-
Eli Lilly and CompanyIncyte Corporation完全的
-
Eli Lilly and Company完全的
-
University of Southern CaliforniaNational Cancer Institute (NCI)终止
-
University of California, DavisNational Cancer Institute (NCI); Novartis Pharmaceuticals完全的
-
Incyte CorporationNovartis Pharmaceuticals完全的
-
SCRI Development Innovations, LLCNovartis完全的
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)招聘中
-
Eli Lilly and CompanyIncyte Corporation完全的